Abstract: Kallikrein-related peptidases KLK5, KLK7 and KLK14 are important proteases in skin desquamation and aberrant KLK activity is associated with inflammatory skin diseases such as Netherton syndrome but also with various serious forms of cancer. Previously, we have identified KLK7 as the first protease target of vaspin (Serpin A12). Here, we report KLK14 as a second KLK protease to be inhibited by vaspin. In conclusion, vaspin represents a multi-specific serpin targeting the kallikrein proteases KLK7 and KLK14, with distinct exosites regulating recognition of these target proteases and opposing effects of heparin binding on the inhibition reaction.
specificity (Egelrud and Lundstrom, 1991) , was identified as the first vaspin target protease . Vaspin did not inhibit the closely related kallikrein proteases KLK4 and KLK5 , which are both proteases with trypsin-like specificity (Debela et al., 2006) . KLK7 is the most abundantly expressed KLK in the stratum corneum (Komatsu et al., 2006) and, with contributions of KLK5 and KLK14, the major enzyme involved in corneocyte shedding (de Veer et al., 2017) . Aberrant activities of these KLKs are related to inflammatory skin diseases such as Netherton syndrome (Kasparek et al., 2017) , psoriasis (Ekholm and Egelrud, 1999) and acne rosacea (Yamasaki et al., 2007) . KLK7 and vaspin have been shown to be coexpressed in human skin as well as in pancreatic islets . KLK14 is a member of the kallikrein family that displays both trypsin-and chymotrypsin-like activity (Felber et al., 2005) and was tested here as a potential target protease of vaspin. Figure 1 demonstrates the inhibitory activity of different vaspin variants against the known protease target KLK7 and the newly identified target KLK14. As previously shown, vaspin wildtype (wt) forms stable serpin-protease complexes with KLK7 ( Figure 1A ) with an apparent molecular weight of ~70 kDa. In comparison, complex formation of vaspin with KLK14 was also observed (Figure 1B) , though complex formation is much slower. Additional bands at a molecular weight of ~44 kDa and ~42 kDa represent fragments derived by proteolytic cleavage of the N-terminus and of the RCL of vaspin, respectively. For KLK7, N-terminal processing after Y 30 of vaspin results in release of a short decapeptide vaspin (L 20 -Y 30 ) . Also with KLK14 we observed specific N-terminal cleavage of vaspin, but after R 28 (Supplementary Figure 1, Supplementary Table 1) , which is in agreement with the strong trypsin-like arginine preference of KLK14 at the P1 position (Felber et al., 2005) . It is unknown, whether these peptides inherit any biological function, as e.g. described for a peptide derived from the N-terminal sequence of PEDF (Serpin F1) (Koskimaki et al., 2012) . The N-terminally truncated vaspin retains full inhibitory activity . Incubation of vaspin with KLK14 yielded an additional protein band with an apparent molecular weight of ~35 kDa ( Figure 1B , 180 min). Tryptic in-gel digestion of the protein band and subsequent mass spectrometry (MS) identified multiple vaspin-derived peptides covering the middle of the molecule (residues 130-280; data not shown). By using a substrate variant of vaspin bearing the A369P mutation, we could demonstrate that this vaspin fragment results from KLK14 cleavage of native or cleaved vaspin but not from specific degradation of the serpin-protease complex ( Figure 1C ). As previously shown, the A369P mutation retards RCL integration into the central β-sheet A and enables the protease to escape the serpin-mechanism by facilitating RCL cleavage (Pippel et al., 2016) .
Chymotrypsin-like KLK7 cleavage in the vaspin RCL has been shown to occur after M 378 , which is in line with reported subsite preferences of KLK7 (Debela et al., 2006) . MS analysis of KLK14-cleaved vaspin revealed the same scissile bond within the RCL sequence as targeted by KLK7 (Supplementary Figure 1 , Supplementary Table 1 ), which is in agreement with previously reported cleavage of the antitrypsin RCL for KLK14 (Felber et al., 2006) . Thus, both proteases attack the same peptide bond between P1 residue M 378 and P1′ residue E
379
. For KLK7, we have demonstrated the repressing effect of E 379 on vaspin activity, as the P1′ site mutation of glutamate to serine (E379S) resulted in substantial acceleration of KLK7 inhibition (Ulbricht et al., 2015) . A scissile bond of P1 Met-P1′ Ser resembles the cleavage site in antitrypsin (Serpin A1), a very good inhibitor of KLK7 and KLK14 (Felber et al., 2006;  (E) Vaspin variants were incubated with KLK14 for 24 h. Human vaspin wt and variants were expressed in and purified from Escherichia coli as described previously (Ulbricht et al., 2015) . KLK7 and KLK14 (both from R&D Systems, Minneapolis, MN, USA) were activated with thermolysin (R&D) according to manufacturer's protocol. Protease (0.5 μm) was incubated with vaspin wt or variant (protease: serpin molar ratio of 2:1) in TBS (20 mm Tris, 150 mm NaCl, pH 7.5) for indicated times. Reactions were stopped by adding reducing SDS sample buffer and immediately heated at 95°C for 5 min. SDS-PAGE was performed as previously described (Ulbricht et al., 2015) and gels were silver stained for protein detection (Thermo Fisher Scientific, Waltham, MA, USA). Indicated bands are: 1 -vaspin-protease complex; 2 -full-length vaspin; 3 -N-terminally cleaved vaspin; 4 -RCL-cleaved vaspin; 5 -vaspin fragment; 6 -protease; 7-thermolysin; con -vaspin only. Luo and Jiang, 2006) . Mutation of the P1 site to a more preferred Tyr (M378Y) only resulted in minor improvement of KLK7 inhibition (Pippel et al., 2016) , demonstrating the P1′ site as the decisive regulatory element of inhibition rate within the RCL.
KLK7 is unable to cleave the synthetic RCL-derived peptide comprising vaspin residues T 365 -K 388 and thus exosite interactions are essential for the efficient inhibition of KLK7 by vaspin (Ulbricht et al., 2015) . To investigate whether exosites are equally important for vaspin activity towards KLK14, the same vaspin RCL-derived peptide was incubated with KLK14. As also observed for KLK7, this peptide was not cleaved by KLK14 (Supplementary Figure 2 ) indicating that the P1′ residue E 379 is also a negative regulatory element for KLK14. This was supported by complex formation analysis using the E379S vaspin mutant ( Figure 1D ). Exchange of P1′ Glu did clearly accelerate the inhibition reaction, though not in the same extent as it does affect the KLK7 inhibition reaction ( Figure 1D ). Together, these data suggest the P1′ glutamate as the primary determinant of specificity for vaspin. Furthermore, these results indicate the requirement of exosite interactions for efficient inhibition of KLK14 by vaspin.
Vaspin residue R 302 , located in the β-sheet C and close to the RCL cleavage site, was identified as the crucial exosite for KLK7 recognition and inhibition (Ulbricht et al., 2015) . Complex formation is much slower and the inhibition rate is significantly decreased for vaspin mutants lacking R 302 ( Figure 1A and Table 1 ). For the inhibition of KLK14, striking differences for the vaspin wt and variants were observed. First and as mentioned before, inhibition of KLK14 by vaspin wt is a significantly slower than inhibition of KLK7, with inhibition rates of 1.0 mm −1 s −1 compared to 12.3 mm −1 s −1 (Table 1) ). These data imply that R 302 is not an essential exosite for KLK14 recognition. Instead, the arginine side chain in the wt seems to slightly hinder serpin protease interaction, affecting both the inhibitory and substrate pathway ( Figure 1B) .
Previously, an artificial disulfide mutant of vaspin (D305C/V383C) showed a five-fold increase in inhibitory activity towards KLK7 (Ulbricht et al., 2015) . We generated the vaspin mutant D305A to investigate this aspartate residue as a potential second exosite regulating or finetuning protease specificity. Indeed, the D305A mutant exhibited a significantly accelerated inhibition rate for KLK7 (89.7 mm −1 s −1
, Table 1 ), suggesting a repulsive effect of the negatively charged side chain on KLK7. The stoichiometry of inhibition (SI) for KLK7 and vaspin D305A was also decreased, indicating a more efficient inhibition reaction compared to the wt (1.8 vs. 3.6, Table 1 ). In contrast, the mutation of D 305 to alanine did not affect KLK14 inhibition and kinetic parameters were similar to the vaspin wt ( Figure 1B , Table 1 ). Densitometric estimation of the SI from SDS-gels also gave comparable values for vaspin wt and variants (Table 1) . Notably, serpin-protease complexes of both mutants, R302A and D305A, were stable for at least 24 h, but KLK14 complexes with vaspin wt were only stable up to 7 h (data not shown) and were not detected after prolonged incubation ( Figure 1E ). Serpinenzyme complexes are cleared from the circulation rather rapidly (Pizzo et al., 1988; Mast et al., 1991) , and the stability time of vaspin-KLK14 complexes should therefore allow potential in vivo relevance. Together, these results demonstrate that vaspin is a multi-specific serpin which utilizes individual exosites for the inhibition of its target proteases despite its unfavored RCL residue on the prime site of the scissile bond. Yet, specific exosite(s) important for KLK14 recognition and inhibition remain unknown.
Alike other common serpins such as antithrombin (Serpin C1), heparin-cofactor II (Serpin D1) or protein C inhibitor (Serpin A5), vaspin is a heparin-binding serpin (NFF3), from Ana Spec, Fremont, CA, USA) and various vaspin concentrations (vaspin: KLK7 ratio 2.5-25:1). SI determination was performed using 19.2 nm KLK7, 10 μm NFF3 and various vaspin concentrations (vaspin: KLK7 ratio 0.25-3:1). For KLK14, a discontinuous method was applied using 4 nm KLK14, 100 μm fluorogenic peptide (Boc-Val-Pro-Arg-AMC, from Bachem, Bubendorf BL, Switzerland) and 100-fold excess of vaspin. Measurements were made after 20 min of incubation time. Residual KLK7 activity was measured on a FlexStation3 Multi-Mode Microplate Reader (Molecular Devices, San Jose, CA, USA). Second-order rate constants for both proteases were determined as described previously (Ulbricht et al., 2015) . SI were estimated using the band intensity of complexed and cleaved vaspin divided by the band intensity of complexed vaspin as described previously (Ulbricht et al., 2015) .
and heparin accelerates KLK7 inhibition by vaspin via the template-bridging mechanism . To evaluate the effect of heparin on KLK14 inhibition, vaspin and KLK14 were incubated in the presence of increasing concentrations of heparin. In contrast to the inhibition of KLK7, the complex formation of KLK14 and vaspin wt was inhibited by heparin for all concentrations investigated (Figure 2A ), yet RCL cleavage still occurred. KLK14-cleaved vaspin in the presence of heparin migrated slightly lower than without heparin which may indicate additional and specific processing in the presence of heparin.
Altered migration of vaspin molecules (full length or cleaved) in the presence of heparin was not observed before . We used MS to analyzed the appearance of additional vaspin peptides after cleavage by KLK14 in the presence of increasing heparin concentrations. While acquisition of peptide and protein spectra was not feasible for higher concentrations of heparin (>1 × mol/mol to vaspin), we did detect additional peptide fragments after incubation of vaspin with KLK14 in the presence of equimolar heparin (data not shown). These peptides were in the range of 5 kDa which is in line with the band shift observed in the SDS-PAGE gels. Yet, we could not detect the corresponding full protein peaks, and due to the size we could not sequence the peptides by MSMS. We conclude that in the presence of heparin there is additional vaspin cleavage by KLK14, but the exact cleavage site remains unclear.
Thus, for vaspin-KLK14 complex formation, heparin binding may block or interfere with crucial, yet unknown exosite interactions. Similar findings have been reported for the reaction of kallistatin (Serpin A4) and tissue kallikrein (KLK1), with heparin preventing protease inhibition by the serpin (Chen et al., 2000) . For kallistatin, a positively charged loop functions as both the heparin binding site (Chen et al., 2001 ) and as exosite contact for KLK1 (Chen et al., 2000) . Yet, while the location of these basic residues in kallistatin is corresponding to R 301 and R 302 of vaspin, our data demonstrated that this position, while essential for KLK7 inhibition, is not contributing to heparin binding , nor is it important for KLK14 inhibition by vaspin. Furthermore, as KLK7 is also inhibited by kallistatin (Luo and Jiang, 2006) , it would be interesting to see how heparin affects the inhibition of KLK7 by kallistatin. The presence of heparin may have similarly opposing effects as observed for vaspin inhibition of KLK7 and KLK14, respectively.
Finally, glycosylation of vaspin has been reported at three different sites (N221, N233 and N267), two of them in close proximity to the RCL . As already demonstrated for KLK7, glycosylation of vaspin also slowed down inhibition of KLK14 compared to unglycosylated vaspin ( Figure 2B ) but did not prevent complex formation.
Recent evidences indicate anti-inflammatory actions as a major function of vaspin. These protective functions SDS-PAGE-analysis of vaspin: KLK14 complex formation with (A) heparin and (B) in HEK-cells. Human vaspin wt expression, purification and activation was performed as described in Figure 1. (A) 0.5 μm protease was incubated with vaspin wt (protease: serpin molar ratio 2:1) in TBS (20 mm Tris, 150 mm NaCl, pH 7.5) for 180 min and indicated vaspin: heparin ratios (unfractionated heparin from Sigma-Aldrich, St. Louis, MO, USA). In contrast to KLK7, complex formation of KLK14 and vaspin wt was inhibited by heparin for all concentrations investigated. (B) A total of 66 nm vaspin wt expressed in HEK-cells (BioLegend, San Diego, CA, USA) was incubated with KLK14 (serpin: protease ratio of 1:1) for indicated times. Glycosylation of vaspin did not prevent complex formation. Samples were analyzed as described in Figure 1 . Indicated bands are: 1 -vaspin-KLK14 complex; 2 -full-length vaspin; 3 -N-terminally cleaved vaspin; 4 -RCL-cleaved vaspin; 5 -vaspin fragment; 6 -KLK14; con -vaspin only.
of vaspin in diverse tissues are exerted via both, regulation of protease activity and interaction with cell surface molecules. Overexpression of vaspin in adipose tissue protects mice from obesity-induced adipose tissue inflammation and insulin resistance and vice versa, with the knock-out of the vaspin gene metabolic functions deteriorate under high fat diet (Nakatsuka et al., 2012) . Interestingly, inactive vaspin mutant A369P failed to improve glucose tolerance in high fat diet-induced insulin resistant mice , suggesting the regulation of protease activity to contribute to these effects. Following the identification of KLK7 as a protease target of vaspin, we have recently shown, that knock out of the Klk7 gene in adipose tissue reduced obesity-induced local and systemic inflammation and improved insulin sensitivity in mice (Zieger et al., 2017) .
Thus, the identification of target proteases, such as KLK7 and also KLK14 will contribute to deeper mechanistic understanding of the protective effects of vaspin in obesity and metabolic diseases. Furthermore, they also may lead to new findings on KLK functions in tissues that have not been in the focus of KLK research yet. For instance, KLK14 is expressed in significant amounts in pancreas and adipose tissue according to the human protein atlas (Uhlén et al., 2015) and it is tempting to speculate on potential functional relevance of KLK14 in obesity and/or diabetes similar to KLK7. Finally, efforts to identify the physiological substrates of KLK7 and KLK14 are key to the detailed understanding of molecular pathways regulated by these proteases. This may lead to new pharmacologic strategies to treat obesity associated diseases.
